Bornstein S, White R, Malkoski S, Reh D, Anderson P, Gross N, Olson S, Deng CX, Lu SL*, Wang XJ: Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation. J Clin Invest. 119: 3408-3419 (2009).
Pub Med ID: 19841536
Malkoski S, Cleaver T, Lu SL, Lighthall J, Wang XJ: Keratin promoter based gene manipulation in the murine conducting airway. Int J. Biol. Sci. 6: 68-79 (2010).
Pub Med ID: 20140084
Bornstein S, Han G, Hoot K, Lu SL, Wang XJ: TGFβ-Mediated Epithelial Mesenchymal Transition and Metastasis in Skin and Head-and-Neck Cancer. In [New Trends in the Molecular and Biological Basis for Clinical Oncology] ed. Tetsuhiko Tachikawa. Springer, pp. 69-80 (2009).
Weber S, Bornstein S, Malkoski S, Herrington H, Andersen P, Corless C, Kulesz-Martin M, Wang XJ, Lu SL*: Tobacco-specific Nitrosamine 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone rapidly induces AKT activation in head and neck squamous cell carcinomas. BMC cancer. (Submitted).
Lu SL, Akiyama Y, Nagasaki H, Saitoh K, Yuasa Y: Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer. Biochem. Biophy. Res. Commun. 216: 452-457 (1995).
Pub Med ID: 7488133
Lu SL, Akiyama Y, Nagasaki H, Nomizu T, Ikeda E, Baba S, Ushio K, Iwama T, Maruyama K, Yuasa Y: Loss or somatic mutations of hMSH2 occur in hereditary nonpolyposis colorectal cancers with hMSH2 germline mutations. Jpn. J. Cancer Res. 87: 279-287 (1996).
Pub Med ID: 8613431
Lu SL, Zhang WC, Akiyama Y, Nomizu T, Yuasa Y: Genomic structure of the transforming growth factor-beta type II receptor gene and its mutations in hereditary nonpolyposis colorectal cancers. Cancer Res. 56: 4595-4598 (1996).
Pub Med ID: 8840968kk
Lu SL, Kawabata M, Imamura T, Akiyama Y, Nomizu T, Miyazono K, Yuasa Y: HNPCC associated with germline mutation in the TGF-beta type II receptor gene. Nature Genet. 19: 17-18 (1998).
Pub Med ID: 9590282
Lu SL, Kawabata M, Imamura T, Miyazono K, Yuasa Y: Two divergent signaling pathways for TGF-beta separated by a mutation of its type II receptor gene. Biochem. Biophy. Res. Commun. 259: 385-390 (1999).
Pub Med ID: 10362519
Bai Y-Q, Akiyama Y, Nagasaki H, Lu SL, Arai T, Morisaki T, Kitamura M, Muto A, Nagashima M, Nomizu T, Iwama T, Itoh H, Baba S, Iwai T, Yuasa Y: Predominant germ-line mutation of the hMSH2 gene in Japanese hereditary non-polyposis colorectal cancer kindreds. Int. J. Cancer 82: 512-515 (1999).
Pub Med ID: 10404063
Brunschwig E, Wilson K, Mack D, Dawson D, Lawrence E, Willson JK, Lu SL, Nosrati A, Rerko RM, Swinler S, Beard L, Lutterbaugh JD, Willis J, Platzer P, Markowitz SD: PMEPA1, a transforming growth factor-beta-induced marker of terminal colonocyte differentiation whose expression is maintained in primary and metastatic colon cancer. Cancer Res. 63: 1568-1575 (2003).
Pub Med ID: 12670906
Yan M, Rerko R, Platzer P, Dawson D, Willis J, Tong M, Lawrence E, Lutterbaugh J, Lu SL, Willson JK, Luo G, Hensold J, Tai, H, Wilson K, Markowitz SD: 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci USA 101: 17468-17473 (2004).
Pub Med ID: 15574495
Lu SL, Reh D, Li AG, Woods J, Corless CL, Kulesz-Martin M, Wang XJ: Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res. 64: 4405-4410 (2004).
Pub Med ID: 15231647
Li AG, Lu SL, Zhang MX, Deng C, Wang XJ: Smad3 knockout mice exhibit a resistance to skin chemical carcinogenesis. Cancer Res. 64: 7836-7845 (2004).
Pub Med ID: 15520189
Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J , Myeroff L, Platzer P, Lu SL, Dawson D, Willis J, Pretlow TP, Lutterbaugh J, Kasturi L, Willson JK, Rao JS, Shuber A, Markowitz SD: Detection in fecal DNA of colon cancer specific methylation of the non-expressed vimentin gene. J Natl Cancer Inst. 97: 1124-1132 (2005).
Li AG, Lu SL, Han G, Kulesz-Martin M, Wang XJ: Current view of the role of transforming growth factor beta1 in skin carcinogenesis. J Investig Dermatol Symp Proc. 10: 110-117 (2005).
Pub Med ID: 16363062
Han G, Lu SL, LiAG, He W, Corless CL, Kulesz-Martin M, Wang XJ: Distinct mechanisms of TGFbeta1-mediated epithelial-mesenchymal transition and metastasis during skin carcinogenesis. J Clin Invest. 115: 1714-1723 (2005).
Koster MI, Lu SL, White LD, Wang XJ, Roop DR: Reactivation of developmentally expressed p63 isoforms predispose to tumor development and progression. Cancer Res. 66: 3981-3986 (2006).
Pub Med ID: 16618715
Han G, Li AG, Liang YY, Owens P, He W, Lu SL, Yoshimatsu Y, Wang D, Lin X, Lu SL, Herrington H, Reh D, Weber S, Bernstein S, Wang D, Tang CF, Siddiqui Y, Nord J, Andersen P, Corless C, Wang XJ: Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev. 20: 1331-1342 (2006).
Pub Med ID: 16702406
Wang XJ: Smad7-induced beta-catenin degradation alters epidermal stem cell differentiation. Developmental Cell 11: 301-12 (2006). Pub Med ID: 16950122
Li AG, Lu SL, Han G, Hoot K, Wang XJ: Role of TGFbeta in skin inflammation and carcinogenesis. Mol Carcinog. 45:389-96 (2006).
Pub Med ID: 16673381
Junttila M, Puustinen P, Niemela M, Ahola R, Nielsen C, Kallunki T, Ivaska J, Arnold H, Lu SL, Wang XJ, Chan EK, Grenman R, Kast J, Sears R, Kahari V, Westermarck J: CIP2A inhibits PP2A in human malignancies. Cell 130:51-62 (2007).
Pub Med ID: 17632056
Bornstein S, Hoot K, Hang G, Lu SL, Wang XJ: Distinct roles of individual Smads in skin carcinogenesis. Mol Carcinog. 46:660-4 (2007).
Pub Med ID: 17477360
Hoot K, Lighthall J, Han G, Lu SL, Han G, Li A, Ju W, Kulesz-Martin M, Bottinger E, Wang XJ: Keratinocyte-specific Smad2 ablation results in increased epithelial-mesenchymal transition during skin cancer formation and progression. J Clin Invest. 118:2722-32. (2008).
Pub Med ID: 18618014
Cohen J, Chen Z, Lu SL, Ehsanian R, Brown M, Arun P, Lu H, Yang X, Yan B, Diallo M, Friedman J, Yeh T, Wang XJ, Van Waes C: Deficient expression of Transforming Growth Factor-β Receptor Type II promotes Nuclear Factor κB activation in head and neck cancers with mutant p53. Cancer Res. 69: 3415-24. (2009)